Prosensa Therapeutics awarded top prize for biotechnology innovation in Europe winning EuropaBio's 2011 Most Innovative Biotech SME Award
At the EuropaBio event entitled "Biotechnology: what's in it for you", hosted at the European Parliament by Julie Girling, MEP, Prosensa Therapeutics was revealed as this year's winner of EuropaBio’s Most Innovative European Biotech SME Award.
The winning SME fought off stiff competition from 26 other applicants from across the EU, all of which demonstrated ground-breaking research in the field of biotechnology in its healthcare, agricultural and industrial applications. The judging panel consisted of G. Steven Burrill, Founding CEO of Burrill and Company; Dr Paul Ruebig, MEP; Tom Saylor, Chair of EuropaBio's SME Platform and CEO of Arecor as well as Nathalie Moll, Secretary General of EuropaBio.
This year's five finalists including AiCuris GmbH & CO., Biocentras, Cardio3 BioSciences and to-BBB, presented their innovative findings to the judging panel and an audience of high-level EU decision makers, CEOs and venture capitalists during the event before the Dutch based company was selected as the over-all winner. During the event, G. Steven Burrill, Founding CEO of Burrill & Company, gave a fascinating keynote address looking back on over 25 years of biotechnology research and applications and looking forward to what our world will look like in 2020 thanks to advances in this unique life enabling technology.
Prosensa Therapeutics was awarded the top prize for their efforts in developing a treatment for Duchenne Muscular Dystrophy (DMD) – an inherited, lethal childhood rare disease. DMD is highly debilitating and gradually weakens muscles to the effect that the child is often left wheelchair bound by the age of 12, with a mean life expectancy of just 25-30 years of age. Currently, there is no effective treatment for DMD. However, Prosensa has one of the world’s most advanced programmes to develop an innovative pipeline of products to treat DMD and its lead product is already in phase III clinical trials.
The award, a prize of €10,000 and two years free membership of EuropaBio was presented by the Judges and Daniel Calleja- Crespo, Deputy Director General DG Industry and Entrepreneurship and EU Commission special envoy for SMEs who also addressed the event detailing the Commission's plans for boosting European SMEs.
EuropaBio warmly welcomes the European Commission’s new proposal on industrial policy for growth and economic recovery. Launched by Vice President Tajani, following extensive consultation and analysis, the Communication builds on the work of the Lead Market Initiative (LMI) and highlights ... more
In an exciting twist, two companies have been announced as winners of EuropaBio’s Most Innovative Biotech SME Award 2012. Commission Vice President Tajani who presented the award, during the event hosted by Dr. Kay Swinburne MEP at the European Parliament, named both Austrian healthcare bi ... more
The world is thirsty because we are hungry,” notes the United Nations on World Water Day. The world’s population reached 7 billion in 2011, and it is predicted to rise to at least 9 billion by 2050. More people living on our planet will require a more efficient use of dwindling natural res ... more
EuropaBio is the political voice of the biotechnology industry in Europe. Our association of bioindustries has some 85 corporate and 7 associate members operating worldwide, 5 Bioregions and 25 national biotechnology associations, representing 1800 small and medium sized biotech companies ... more
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
The company's product portfolio is comprised of two approved products and multiple investigational product candidates. Approved products include Naglazyme® (galsulfase) for mucop ... more
BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and lif ... more